10:42 AM EST, 12/17/2025 (MT Newswires) -- Structure Therapeutics ( GPCR ) started a first-in-human Phase 1 trial of ACCG-2671, an oral drug designed to activate the amylin receptor, a pathway involved in regulating appetite and weight.

The study will assess the safety, tolerability, and how the drug is processed and acts in the body in both healthy volunteers and people with obesity, the company said Wednesday in a statement.

ACCG-2671 was designed through Structure Therapeutics' ( GPCR ) drug discovery platform to use the benefits of amylin biology in an oral, once-daily small molecule. The trial will include single-ascending dose and multiple-ascending dose groups.

Price: 60.89, Change: -0.82, Percent Change: -1.33